Cawston Erin E, Redmond William J, Breen Courtney M, Grimsey Natasha L, Connor Mark, Glass Michelle
Centre for Brain Research and Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Br J Pharmacol. 2013 Oct;170(4):893-907. doi: 10.1111/bph.12329.
The cannabinoid receptor type 1 (CB1 ) has an allosteric binding site. The drugs ORG27569 {5-chloro-3-ethyl-N-[2-[4-(1-piperidinyl)phenyl]ethyl]-1H-indole-2-carboxamide} and PSNCBAM-1 {1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea} have been extensively characterized with regard to their effects on signalling of the orthosteric ligand CP55,940 {(-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol}, and studies have suggested that these allosteric modulators increase binding affinity but act as non-competitive antagonists in functional assays. To gain a deeper understanding of allosteric modulation of CB1 , we examined real-time signalling and trafficking responses of the receptor in the presence of allosteric modulators.
Studies of CB1 signalling were carried out in HEK 293 and AtT20 cells expressing haemagglutinin-tagged human and rat CB1 . We measured real-time accumulation of cAMP, activation and desensitization of potassium channel-mediated cellular hyperpolarization and CB1 internalization.
ORG27569 and PSNCBAM-1 produce a complex, concentration and time-dependent modulation of agonist-mediated regulation of cAMP levels, as well as an increased rate of desensitization of CB1 -mediated cellular hyperpolarization and a decrease in agonist-induced receptor internalization.
Contrary to previous studies characterizing allosteric modulators at CB1, this study suggests that the mechanism of action is not non-competitive antagonism of signalling, but rather that enhanced binding results in an increased rate of receptor desensitization and reduced internalization, which results in time-dependent modulation of cAMP signalling. The observed effect of the allosteric modulators is therefore dependent on the time frame over which the signalling response occurs. This finding may have important consequences for the potential therapeutic application of these compounds.
1型大麻素受体(CB1)具有一个变构结合位点。药物ORG27569{5-氯-3-乙基-N-[2-[4-(1-哌啶基)苯基]乙基]-1H-吲哚-2-甲酰胺}和PSNCBAM-1{1-(4-氯苯基)-3-[3-(6-吡咯烷-1-基吡啶-2-基)苯基]脲}已就其对正构配体CP55,940{(-)-顺式-3-[2-羟基-4-(1,1-二甲基庚基)苯基]-反式-4-(3-羟丙基)环己醇}信号传导的影响进行了广泛表征,研究表明这些变构调节剂可增加结合亲和力,但在功能测定中表现为非竞争性拮抗剂。为了更深入地了解CB1的变构调节,我们研究了变构调节剂存在时受体的实时信号传导和转运反应。
在表达血凝素标记的人源和大鼠源CB1的HEK 293细胞和AtT20细胞中进行CB1信号传导研究。我们测量了cAMP的实时积累、钾通道介导的细胞超极化的激活和脱敏以及CB1的内化。
ORG27569和PSNCBAM-1对激动剂介导的cAMP水平调节产生复杂的、浓度和时间依赖性的调节,以及CB1介导的细胞超极化脱敏速率增加和激动剂诱导的受体内化减少。
与之前对CB1变构调节剂的研究相反,本研究表明其作用机制不是信号传导的非竞争性拮抗,而是增强的结合导致受体脱敏速率增加和内化减少,从而导致cAMP信号传导的时间依赖性调节。因此,观察到的变构调节剂的作用取决于信号反应发生的时间框架。这一发现可能对这些化合物的潜在治疗应用产生重要影响。